is expected that by 2030 pancreatic cancer incidence will have increased by approximately 100% and pancreatic cancer mortality by about 70%. 2, 3 Thus, pancreatic cancer is expected to play a more important part in cancer burden in the years to come.
Epidemiological studies are important tools to better comprehend the burden of pancreatic cancer. Among these studies, multiinstitutional and nationwide registries constitute important means to obtain data about this disease. 4, 5 Nevertheless, registries may be flawed as they often do not have access to detailed information on prognostic features and treatment outcomes. Also, they may underestimate the consequences of the disease in the studied populations, even in small countries with organized cancer databases. 6 In Brazil, there is limited information on the epidemiological burden of pancreatic cancer [7] [8] [9] and national cancer databases sponsored by the government suffer from significant problems, such as underreporting of incident cases and deaths. 10, 11 Therefore, other sources of information should be explored to better understand the population of patients treated for pancreatic cancer.
Comprehensive single-hospital series of patients with pancreatic cancer, especially in large cancer centers, can provide significant patientcentered information. In this setting, detailed data about patients' characteristics, treatments, and outcomes can be obtained. Besides, data from these series can be compared to those found in broader databases so that differences in disease control, diagnosis, and management can be detected. 12 This may lead to improvements in patient care through critical assessment of treatment results, treatment standardization, and consolidation of multidisciplinary pancreatic cancer management. 13 We performed a retrospective study evaluating the patients with the diagnosis of exocrine pancreatic cancer seen at AC Camargo Cancer Center (ACCCC) from 2008 to 2016. The primary objective was to describe their demographical and clinico-pathological characteristics. Also, we aimed to describe the overall survival of these patients according to the stage at diagnosis.
| METHODS
This is a single center, retrospective cohort study based on routinely collected data extracted from the electronic medical records. Data collection was standardized and performed by seven investigators.
After the first variable operationalization, we performed a pilot study comprising 25 randomly selected patients. Then, we accessed the collected data for concordance among all seven investigators.
Afterward, a second variable operationalization was performed and a training meeting was scheduled to improve the quality of the extracted data. This study has been approved and registered by the ACCCC Internal Ethics Review Board under the number 2420/17
(CAAE 73191617.0.0000.5432).
| Patients
We searched in the ACCCC database for the electronic medical records of patients with the diagnosis of pancreatic cancer using the terms "C25" and "pancreatic AND cancer" (from January 1st 2008 to January 17th 2017).
The following patients were included: (1) 18-year old or older, (2) who attended at least one visit at ACCCC, (3) had histologically confirmed diagnosis of malignant exocrine pancreatic neoplasm, (4) and were diagnosed from January 1st 2008 to December 31th 2016.
We excluded the following patients: (1) those with unknown data of diagnosis, or (2) no tumor biopsy. All consecutive patients meeting eligibility criteria were included in the analysis.
| Variables
We collected data about the following characteristics: age at 
| Statistical analysis
Distributions of categorical variables were described using absolute frequencies and simple ratios. Distributions of numerical variables were summarized using median values and interquartile ranges (IQR). We used the Kaplan-Meier method to generate survival curves. Overall survival was defined as the time from diagnosis to time of death from any cause. Patients alive were censored at the last follow-up date. Statistical analysis was performed in R Project software (version 3.4.0).
| RESULTS

| Descriptive statistics
We found 1576 patients in the database using the search criteria.
Among these, 831 were found to have a diagnosis of malignant exocrine pancreatic tumor ( Figure 1 ). After excluding ineligible patients, 739 patients were encountered. Table 1 
| Temporal trends in new pancreatic cancer cases
We observed a constant upward trend in the number of patients diagnosed with pancreatic cancer that attended at least one visit at ACCCC from 2008 to 2016. In addition, the proportion of patients diagnosed in each stage category was similar throughout the study's time span (Figure 2 ).
| Treatment and survival
Among 241 patients with potentially resectable disease at diagnosis, 177 were submitted to potentially curative surgery (107 at ACCCC). 
| DISCUSSION
In recent years, more attention has been paid to pancreatic cancer due to its increasing epidemiological burden. Proper characterization of the patients affected by pancreatic cancer is paramount to determine the population at risk for developing the disease. That may enable the implementation of effective population-based preventive measures and personalized treatment strategies.
The most important risk factor for pancreatic cancer is advanced age. 14 In our study, the median age at diagnosis of pancreatic cancer was 64 years, less than that observed in the USA according to the Surveillance and Epidemiology and End Results-71 years. 15 Our data more closely approach those of European registries and audits, in which the median age at diagnosis of pancreatic cancer ranged from 64.2 to 69 years. 5 This difference in age may reflect a selection bias, as patients with more advanced age and decreased physiological reserve may not have the opportunity to be referred in time to a tertiary cancer center for adequate treatment.
A family history of pancreatic cancer up to second-degree relatives was found in 4.8% of patients. Accordingly, previous studies have shown that approximately 5% to 10% of patients with pancreatic cancer present with positive family history for the disease. 16 In addition, an expressive number of patients had relatives affected by other types of cancer. This is relevant, because these patients may present genetic syndromes associated with increased risk for pancreatic cancer and their relatives may be candidates for cancer screening. Also, some germline genetic alterations, especially in the homologous recombination pathway, render the tumor more sensitive to specific treatments, such as platinum-based Possibly, in the years to come, this information will also be used to tailor systemic treatment in patients with pancreatic cancer. As a consequence, further assessment of the role of inherited cancer syndromes in the etiology of pancreatic cancer in our population is warranted.
Our data on primary tumor site and stage at diagnosis match those found in the literature. Approximately two-thirds of pancreatic cancers arise in the pancreatic head region 19 and around 50% of patients present with metastatic disease at diagnosis. 20 However, we describe more patients with a potentially resectable disease when compared to previous data. 21 That may be a consequence of having included patients with anatomical borderline pancreatic cancer in this group. Previously, many of these patients were considered inadequate for surgery with curative intent. 22 Recently, improvements in imaging, surgical techniques, preoperative chemotherapy and postoperative care, along with the expansion of a multidisciplinary approach to pancreatic cancer, have prompted changes in the definitions of resectability and enabled resections in patients with anatomical borderline lesions. In addition, reference bias may also explain a large number of patients with the potentially resectable disease, as ACCCC has been a nationwide reference in high-complexity surgery for decades.
Previous epidemiological studies performed in developed countries have demonstrated a significant increase in the incidence of pancreatic cancer. 2 Similarly, data from government-sponsored databases in Brazil point to a nearly twofold increase in the incidence of pancreatic cancer over the last decade. 8 While this may stem from improvements in our country's notification systems, the upward trends in the number of new pancreatic cancer cases seen in our institution ratify the findings of population-based studies. Altogether, these data reinforce the increasing nationwide burden of pancreatic cancer.
Survival outcomes in our study compare favorably to the ones described in national cancer databases. In a recent analysis of the National Cancer Database (NCDB) from the United States, the median overall survival of patients submitted to pancreatectomy and adjuvant chemotherapy was 26.4 months. 23 In the best-case scenario, when patients were treated with neoadjuvant and adjuvant chemotherapy, median overall survival was 31.2 months. Although the differences in survival between patients treated in our institution and those from national cancer databases might to some extent be explained by patient selection, it is largely known that the outcomes of patients with pancreatic cancer are improved when they are treated in high-volume centers, and that seems to be especially true when it comes to surgical outcomes. 24, 25 Also, overall survival in our study is superior to the ones found in recent randomized trials.
Patients submitted to surgery at ACCCC had median overall survival of 35.4 months, superior to the median overall survival of the Gemcitabine plus Capecitabine arm from the ESPAC-4 trial (28.0 months). 26 That occurred despite the fact that some of the patients in our study presented anatomical borderline disease. We believe these favorable survival results may stem from a more liberal use of neoadjuvant treatment using FOLFIRINOX with or without radiotherapy. 27 Nonetheless, a definitive conclusion about the role of neoadjuvant chemotherapy in resectable pancreatic cancer waits for the results of ongoing randomized controlled trials.
Likewise, the survival of patients with locally advanced disease in our study was superior to that of a recent randomized trial-LAP07. 28 Our results also compare favorably to the ones found in national cancer databases. In a recent study using the NCDB from the United States, the median overall survival of patients with locally advanced pancreatic cancer treated with concurrent chemoradiation was 12.0 months. 29 We believe the use of new and more active chemotherapy regimens as part of an induction treatment may very well have contributed to the relatively good survival of our patients. 29, 30 In our study, the overall survival of patients with metastatic disease at diagnosis was 9.3 months. This is slightly superior to the survival found in the pivotal MPACT trial, that assessed the activity of the combination of Gemcitabine plus NabPaclitaxel in the first-line setting. 31 It also exceeds by far the overall survival of patients assessed through national cancer databases, 32 highlighting the potential benefit of centralized pancreatic cancer also in the metastatic setting. 33 Therefore, we believe the incorporation of new chemotherapeutic regimens and treatment techniques has favorably impacted the outcomes of patients with advanced pancreatic cancer in recent years.
Our study has some limitations. As a retrospective, single-center investigation, we acknowledge that selection bias may be present. In addition, having included some patients that visited our hospital looking for the second opinion, our study does not necessarily describe the outcome of patients treated solely in our institution.
Moreover, we did not provide detailed information regarding ethnicity, socioeconomic status, comorbidities, tumor size, and staging according to tumor node metastasis (TNM) criteria. Despite these limitations, this study portrays, to our knowledge, the largest single-center series of patients with pancreatic cancer in Brazil. We provide important demographical and clinical information of this population, along with relevant survival data. We think continuous efforts should be directed to set up national multicenter databases to better understand and characterize the epidemiology of pancreatic cancer in Brazil. That could add detailed information to the national estimates generated by governmental agencies.
| CONCLUSIONS
In conclusion, exocrine pancreatic cancer remains an important cause of cancer-related mortality. Survival outcomes in our institution compare favorably to the ones found in recent pancreatic cancer trials. Also, adequate profiling of the patients affected by the disease may enable the execution of effective preventive and screening F I G U R E 3 Overall survival of pancreatic cancer patients seen at AC Camargo Cancer Center (ACCCC) according to the stage at diagnosis programs. It may also help customize patient management, such as treatment intensification or enrollment into clinical trials. In Brazil, to optimize the abovementioned strategies, further efforts should be made to glean adequate data on patients with pancreatic cancer.
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